Abstract
Glaucoma is one of the leading causes of irreversible blindness worldwide. However, there are no biomarkers that accurately help clinicians perform an early diagnosis or detect patients with a high risk of progression. Metabolomics is the study of all metabolites in an organism, and it has the potential to provide a biomarker. This review summarizes the findings of metabolomics in glaucoma patients and explains why this field is promising for new research. We identified published studies that focused on metabolomics and ophthalmology. After providing an overview of metabolomics in ophthalmology, we focused on human glaucoma studies. Five studies have been conducted in glaucoma patients and all compared patients to healthy controls. Using mass spectrometry, significant differences were found in blood plasma in the metabolic pathways that involve palmitoylcarnitine, sphingolipids, vitamin D-related compounds, and steroid precursors. For nuclear magnetic resonance spectroscopy, a high glutamine-glutamate/creatine ratio was found in the vitreous and lateral geniculate body; no differences were detected in the optic radiations, and a lower N-acetylaspartate/choline ratio was observed in the geniculocalcarine and striate areas. Metabolomics can move glaucoma care towards a personalized approach and provide new knowledge concerning the pathophysiology of glaucoma, which can lead to new therapeutic options.
References
1.
Oliver SG, Winson MK, Kell DB, Baganz F: Systematic functional analysis of the yeast genome. Trends Biotechnol 1998;16:373-378.
2.
Nicholson JK, Lindon JC, Holmes E: “Metabonomics”: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-1189.
3.
Faber JH, Malmodin D, Toft H, Maher AD, Crockford D, Holmes E, et al: Metabonomics in diabetes research. J Diabetes Sci Technol 2007;1:549-557.
4.
Warburg O, Wind F, Negelein E: The metabolism of tumors in the body. J Gen Physiol 1927;8:519-530.
5.
Kell DB, Brown M, Davey HM, Dunn WB, Spasic I, Oliver SG: Metabolic footprinting and systems biology: the medium is the message. Nat Rev Microbiol 2005;3:557-565.
6.
Nicholson JK, Wilson ID: Opinion: understanding “global” systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2003;2:668-676.
7.
Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, et al: Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics 2016;12:149.
8.
Li S, Todor A, Luo R: Blood transcriptomics and metabolomics for personalized medicine. Comput Struct Biotechnol J 2016;14:1-7.
9.
Himmelreich U MC, Sorrell TC: NMR spectroscopic determination of microbiological profiles in infectious diseases. Trends Appl Spectrosc 2004;269-283.
10.
Doganay S, Cankaya C, Alkan A: Evaluation of corpus geniculatum laterale and vitreous fluid by magnetic resonance spectroscopy in patients with glaucoma: a preliminary study. Eye (Lond) 2012;26:1044-1051.
11.
Burgess LG, Uppal K, Walker DI, Roberson RM, Tran V, Parks MB, et al: Metabolome-wide association study of primary open angle glaucoma. Invest Ophthalmol Vis Sci 2015;56:5020-5028.
12.
Mayordomo-Febrer A, Lopez-Murcia M, Morales-Tatay JM, Monleon-Salvado D, Pinazo-Duran MD: Metabolomics of the aqueous humor in the rat glaucoma model induced by a series of intracamerular sodium hyaluronate injection. Exp Eye Res 2015;131:84-92.
13.
Boucard CC, Hoogduin JM, van der Grond J, Cornelissen FW: Occipital proton magnetic resonance spectroscopy (1H-MRS) reveals normal metabolite concentrations in retinal visual field defects. PLoS One 2007;2:e222.
14.
Zhang Y, Chen X, Wen G, Wu G, Zhang X: Proton magnetic resonance spectroscopy ((1)H-MRS) reveals geniculocalcarine and striate area degeneration in primary glaucoma. PLoS One 2013;8:e73197.
15.
Chan KC, So KF, Wu EX: Proton magnetic resonance spectroscopy revealed choline reduction in the visual cortex in an experimental model of chronic glaucoma. Exp Eye Res 2009;88:65-70.
16.
Sidek S, Ramli N, Rahmat K, Ramli NM, Abdulrahman F, Kuo TL: In vivo proton magnetic resonance spectroscopy (1H-MRS) evaluation of the metabolite concentration of optic radiation in primary open angle glaucoma. Eur Radiol 2016;26:4404-4412.
17.
Osborn MP, Park Y, Parks MB, Burgess LG, Uppal K, Lee K, et al: Metabolome-wide association study of neovascular age-related macular degeneration. PLoS One 2013;8:e72737.
18.
Lains I, Kelly RS, Lasky-Su J, Murta JN, Miller JB, et al: Plasma mass-spectrometry metabolomics in age-related macular degeneration. Abstract Am Assoc Res Vis Ophthalmol Annu Meet, Baltimore, 2017.
19.
Laíns I, Duarte D, Barros AS, Martins AS, Gil J, Miller JB, et al: Human plasma metabolomics in age-related macular degeneration (AMD) using nuclear magnetic resonance spectroscopy. PLoS One 2017;12:e0177749.
20.
Barba I, Garcia-Ramirez M, Hernandez C, Alonso MA, Masmiquel L, Garcia-Dorado D, et al: Metabolic fingerprints of proliferative diabetic retinopathy: an 1H-NMR-based metabonomic approach using vitreous humor. Invest Ophthalmol Vis Sci 2010;51:4416-4421.
21.
Li X, Luo X, Lu X, Duan J, Xu G: Metabolomics study of diabetic retinopathy using gas chromatography-mass spectrometry: a comparison of stages and subtypes diagnosed by Western and Chinese medicine. Mol Biosyst 2011;7:2228-2237.
22.
Chen L, Cheng CY, Choi H, Ikram MK, Sabanayagam C, Tan GS, et al: Plasma metabonomic profiling of diabetic retinopathy. Diabetes 2016;65:1099-1108.
23.
Karamichos D, Zieske JD, Sejersen H, Sarker-Nag A, Asara JM, Hjortdal J: Tear metabolite changes in keratoconus. Exp Eye Res 2015;132:1-8.
24.
Barbas-Bernardos C, Armitage EG, Garcia A, Merida S, Navea A, Bosch-Morell F, et al: Looking into aqueous humor through metabolomics spectacles - exploring its metabolic characteristics in relation to myopia. J Pharm Biomed Anal 2016;127:18-25.
25.
Ji Y, Rao J, Rong X, Lou S, Zheng Z, Lu Y: Metabolic characterization of human aqueous humor in relation to high myopia. Exp Eye Res 2017;159:147-155.
26.
Li M, Li H, Jiang P, Liu X, Xu D, Wang F: Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis. Mol Biosyst 2014;10:1055-1062.
27.
Young SP, Nessim M, Falciani F, Trevino V, Banerjee SP, Scott RA, et al: Metabolomic analysis of human vitreous humor differentiates ocular inflammatory disease. Mol Vis 2009;15:1210-1217.
28.
Guo J, Yan T, Bi H, Xie X, Wang X, Guo D, et al: Plasma metabonomics study of the patients with acute anterior uveitis based on ultra-performance liquid chromatography-mass spectrometry. Graefes Arch Clin Exp Ophthalmol 2014;252:925-934.
29.
Galbis-Estrada C, Martinez-Castillo S, Morales JM, Vivar-Llopis B, Monleon D, Diaz-Llopis M, et al: Differential effects of dry eye disorders on metabolomic profile by 1H nuclear magnetic resonance spectroscopy. Biomed Res Int 2014;2014:542549.
30.
Galbis-Estrada C, Pinazo-Duran MD, Martinez-Castillo S, Morales JM, Monleon D, Zanon-Moreno V: A metabolomic approach to dry eye disorders: the role of oral supplements with antioxidants and omega 3 fatty acids. Mol Vis 2015;21:555-567.
31.
Zhou L, Beuerman RW: Tear analysis in ocular surface diseases. Prog Retin Eye Res 2012;31:527-550.
32.
Munoz-Hernandez AM, Galbis-Estrada C, Santos-Bueso E, Cuina-Sardina R, Diaz-Valle D, Gegundez-Fernandez JA, et al: Human tear metabolome. Arch Soc Esp Oftalmol 2016;91:157-159.
33.
Brown JC, Sadler PJ, Spalton DJ, Juul SM, Macleod AF, Sonksen PH: Analysis of human aqueous humour by high resolution 1H NMR spectroscopy. Exp Eye Res 1986;42:357-362.
34.
Tkadlecová M, Havlíček J, Volka K, Souček P, Karel I: Study of aqueous humour by 1H NMR spectroscopy. J Mol Struct 1999;480-481:601-605.
35.
Berkowitz BA, Bansal N, Wilson CA: Non-invasive measurement of steady-state vitreous lactate concentration. NMR Biomed 1994;7:263-268.
36.
Rucker JC, Biousse V, Mao H, Sandbach J, Constantinidis I, Newman NJ: Detection of lactate in the human vitreous body using proton magnetic resonance spectroscopy. Arch Ophthalmol 2003;121:909-911.
37.
Midelfart A, Dybdahl A, Gribbestad IS: Metabolic analysis of the rabbit cornea by proton nuclear magnetic resonance spectroscopy. Ophthalmic Res 1996;28:319-329.
38.
Priyadarsini S, McKay TB, Sarker-Nag A, Allegood J, Chalfant C, Ma JX, et al: Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. Exp Eye Res 2016;153:90-100.
39.
Saether O, Krane J, Risa O, Cejkova J, Midelfart A: High-resolution MAS 1H NMR spectroscopic analysis of rabbit cornea after treatment with dexamethasone and exposure to UV-B radiation. Curr Eye Res 2005;30:1041-1049.
40.
Chen L, Li J, Guo T, Ghosh S, Koh SK, Tian D, et al: Global metabonomic and proteomic analysis of human conjunctival epithelial cells (IOBA-NHC) in response to hyperosmotic stress. J Proteome Res 2015;14:3982-3995.
41.
Midelfart A, Dybdahl A, Gribbestad S: Detection of different metabolites in the rabbit lens by high resolution 1H NMR spectroscopy. Curr Eye Res 1996;15:1175-1181.
42.
Tsentalovich YP, Verkhovod TD, Yanshole VV, Kiryutin AS, Yanshole LV, Fursova A, et al: Metabolomic composition of normal aged and cataractous human lenses. Exp Eye Res 2015;134:15-23.
43.
Kingman S: Glaucoma is second leading cause of blindness globally. Bull World Health Organ 2004;82:887-888.
44.
Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267.
45.
Moroi SE, Raoof DA, Reed DM, Zollner S, Qin Z, Richards JE: Progress toward personalized medicine for glaucoma. Expert Rev Ophthalmol 2009;4:145-161.
46.
Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. London, National Institute for Health and Clinical Excellence: Guidance, 2009.
47.
Terminology and Guidelines for Glaucoma, ed 4. Zug, European Glaucoma Society, 2014.
48.
International Council of Ophthalmology: ICO Guidelines for Glaucoma Eye Care. San Francisco, ICO, 2016.
49.
Burr JM, Botello-Pinzon P, Takwoingi Y, Hernandez R, Vazquez-Montes M, Elders A, et al: Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. Health Technol Assess 2012;16:1-271, iii-iv.
50.
American Academy of Ophthalmology: Preferred Practice Patterns: Open-Angle Glaucoma. San Francisco, AAO, 2015.
51.
Tuulonen A: Challenges of glaucoma care - high volume, high quality, low cost. Acta Ophthalmol 2013;91:3-5.
52.
Tuulonen A, Kataja M, Syvanen U, Miettunen S, Uusitalo H: Right services to right patients at right time in right setting in Tays Eye Centre. Acta Ophthalmol 2016;94:730-735.
53.
Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, et al: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010;70:8309-8318.
54.
Piszcz J, Armitage EG, Ferrarini A, Ruperez FJ, Kulczynska A, Bolkun L, et al: To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients. Oncotarget 2016;7:22324-22338.
55.
Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al: Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453.
56.
Yin X, Subramanian S, Willinger CM, Chen G, Juhasz P, Courchesne P, et al: Metabolite signatures of metabolic risk factors and their longitudinal changes. J Clin Endocrinol Metab 2016;101:1779-1789.
57.
Flammer J, Konieczka K, Flammer AJ: The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J 2013;4:14.
58.
Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al: Flammer syndrome. EPMA J 2014;5:11.
59.
Furlanetto RL, De Moraes CG, Teng CC, Liebmann JM, Greenfield DS, Gardiner SK, et al: Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study. Am J Ophthalmol 2014;157:945-952.
60.
Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al: The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002;21:359-393.
61.
Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF: Neuroprotection in glaucoma - is there a future role? Exp Eye Res 2010;91:554-566.
62.
Song W, Huang P, Zhang C: Neuroprotective therapies for glaucoma. Drug Des Devel Ther 2015;9:1469-1479.
63.
Weinreb RN: Glaucoma neuroprotection: what is it? Why is it needed? Can J Ophthalmol 2007;42:396-398.
64.
Benoist d'Azy C, Pereira B, Chiambaretta F, Dutheil F: Oxidative and anti-oxidative stress markers in chronic glaucoma: a systematic review and meta-analysis. PLoS One 2016;11:e0166915.
65.
Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA: Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996;114:299-305.
66.
Honkanen RA, Baruah S, Zimmerman MB, Khanna CL, Weaver YK, Narkiewicz J, et al: Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol 2003;121:183-188.
67.
Lodi A, Tiziani S, Khanim FL, Gunther UL, Viant MR, Morgan GJ, et al: Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease. PLoS One 2013;8:e56422.
68.
Tan SZ, Begley P, Mullard G, Hollywood KA, Bishop PN: Introduction to metabolomics and its applications in ophthalmology. Eye (Lond) 2016;30:773-783.
69.
Midelfart A: Metabonomics - a new approach in ophthalmology. Acta Ophthalmol 2009;87:697-703.
70.
Lenz EM, Bright J, Wilson ID, Hughes A, Morrisson J, Lindberg H, et al: Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal 2004;36:841-849.
71.
Johnson JM, Yu T, Strobel FH, Jones DP: A practical approach to detect unique metabolic patterns for personalized medicine. Analyst 2010;135:2864-2870.
72.
Chen R, Snyder M: Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med 2013;5:73-82.
73.
Himmelreich U, Sorrell TC, Daniel HM: Nuclear magnetic resonance spectroscopy-based identification of yeast. Methods Mol Biol 2017;1508:289-304.
74.
Croitor-Sava A, Beck V, Sandaite I, Van Huffel S, Dresselaers T, Claus F, et al: High-resolution (1)H NMR spectroscopy discriminates amniotic fluid of fetuses with congenital diaphragmatic hernia from healthy controls. J Proteome Res 2015;14:4502-4510.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
